Advancing gene editing with new CRISPR/Cas9 variant

December 03, 2020

Using a new variant to repair DNA will improve both safety and effectiveness of the much-touted CRISPR-Cas9 tool in genetic research, Michigan Medicine researchers say.

Those two key problems - safety and efficacy - are what continue to hold CRISPR-Cas9 gene targeting back from its full clinical potential, explains co-senior author Y. Eugene Chen, M.D., Ph.D., a professor of internal medicine, cardiac surgery, physiology, pharmacology and medicinal chemistry, from the Michigan Medicine Frankel Cardiovascular Center.

The new CRISPR-Cas9 variant improves efficiency when inserting a gene or DNA fragment to a precise location in the genome, known as knocking in. It also reduces the rate of unintended insertions or deletions, known as indels, of base pairs that often happen while gene editing.

"We name it meticulous integration Cas9, or miCas9, to reflect its extraordinary capacity to enable maximum integration, yet with minimal indels, as well as to recognize its development at the University of Michigan," write senior authors Chen, Jifeng Zhang and Jie Xu for Nature's "Behind the Paper" series. "It provides a 'one small stone for three birds' tool in gene editing."
-end-
The team previously reported Cas9 genome editing in 2014, and reported beneficial effects of a RAD51 agonist, RS-1, in gene editing in 2016.

Disclosure: Authors Xu, Chen and Xiaofeng Xia are equity holders of ATGC Inc., a licensee of the miCas9 technology from the University of Michigan.

Michigan Medicine - University of Michigan

Related Gene Articles from Brightsurf:

NIH gene therapy startup to increase AAV gene therapy efficiency
Maximizing the efficiency of the adeno-associated virus (AAV) platform for gene therapy is the aim of a new pilot project of the National Institutes of Health (NIH).

Alzheimer's risk gene disrupts endocytosis, but another disease-linked gene could help
MIT researchers find that astrocytes with the risk-increasing APOE4 variant show deficits of key cellular function called endocytosis, but overexpressing another Alzheimer's associated gene, PICALM, overcame the defect

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

Unraveling gene expression
EPFL chemists have uncovered the first steps in the process of gene expression by showing how the protein Rap1 pries open the tightly wound, compacted structure of DNA in the cell to gain access to specific genes.

Gene coding error found in rare, inherited gene cof lung-scarring disorder linked to short telomeres
By combing through the entire genetic sequences of a person with a lung scarring disease and 13 of the person's relatives, Johns Hopkins Medicine researchers say they have found a coding error in a single gene that is likely responsible for a rare form of the disease and the abnormally short protective DNA caps on chromosomes long associated with it.

The two faces of the Jekyll gene
Genes which are specific to a species or group of species can reflect important genetic changes within lineages.

Gene therapy vectors carrying the telomerase gene do not increase the risk of cancer
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.

Blindness gene discovered
Researchers from UNIGE have investigated a recessive genetic disorder that destroys the eyes from developing and results in childhood blindness.

Gene editing just got easier
An international team of researchers has made CRISPR technology more accessible and standardized by simplifying its complex implementation in a way that offers a broad platform for off-the shelf genome engineering.

Read More: Gene News and Gene Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.